HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ(9)-tetrahydrocannabinol in the rat.

Abstract
Cannabinoid agonists such as Δ(9)-tetrahydrocannabinol (THC) are more potent and/or efficacious antinociceptive agents in female than male rats using acute pain models. We tested the hypothesis that THC is more effective in females than males using a model of longer-lasting, inflammatory pain. THC's anti-allodynic, anti-hyperalgesic, and anti-edema effects were examined 1, 3, and 7 days after injection of complete Freund's adjuvant (CFA) into the hind paw. Systemically administered THC (0.32-3.2mg/kg, intraperitoneally [i.p.], same dose each day) was significantly more effective in females than males in attenuating CFA-induced thermal hyperalgesia, but was also more sedative in females. When administered locally into the inflamed hind paw, THC (250-500 μg intraplantar, i.pl.) did not affect locomotor activity in either sex, yet produced greater anti-allodynic and anti-hyperalgesic effects in females than males. Despite THC's greater anti-allodynic and anti-hyperalgesic effects in females, both i.p. and i.pl. THC reduced hind paw thickness (edema) more in males. The anti-hyperalgesic effect of i.p. THC was blocked by the CB1 receptor-selective antagonist rimonabant in both sexes. Similarly, i.pl. rimonabant antagonized i.pl. THC's effects in both sexes; in contrast, the CB2 antagonist SR144528 significantly attenuated i.pl. THC's anti-allodynic effect only in females. Intraplantar SR144528 also antagonized i.pl. THC's anti-edema effect in males. This study suggests that cannabinoids may be better at reducing edema in males while being more effective against inflammatory pain in females. Furthermore, sex differences in THC's peripheral effects against inflammatory pain may be a result of activation of both types of cannabinoid receptors in females, in contrast to predominantly CB1 receptors in males.
AuthorsRebecca M Craft, Ram Kandasamy, Seth M Davis
JournalPain (Pain) Vol. 154 Issue 9 Pg. 1709-1717 (Sep 2013) ISSN: 1872-6623 [Electronic] United States
PMID23707295 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Camphanes
  • Cannabinoid Receptor Agonists
  • Cannabinoid Receptor Antagonists
  • Piperidines
  • Pyrazoles
  • SR 144528
  • Dronabinol
  • Rimonabant
Topics
  • Animals
  • Camphanes (therapeutic use)
  • Cannabinoid Receptor Agonists (therapeutic use)
  • Cannabinoid Receptor Antagonists (therapeutic use)
  • Dose-Response Relationship, Drug
  • Dronabinol (therapeutic use)
  • Edema (chemically induced, drug therapy, etiology)
  • Estrous Cycle (drug effects)
  • Female
  • Hyperalgesia (drug therapy, etiology)
  • Male
  • Motor Activity (drug effects)
  • Pain Measurement
  • Pain Threshold (drug effects)
  • Piperidines (therapeutic use)
  • Pyrazoles (therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Rimonabant
  • Sex Characteristics
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: